For many women, menopause comes with symptoms that can significantly affect their quality of life. Hot flashes, night sweats, sleep disturbances, mood changes, and vaginal dryness are just some of the challenges that can arise during this transition.
Menopausal hormone therapy (MHT) is one of the most effective treatments available for managing many of these symptoms. However, for more than two decades, hormone therapy has been surrounded by confusion, fear, and conflicting information.
Much of this uncertainty can be traced back to a single study published in 2002: the Women's Health Initiative (WHI).
So, what happened in 2002, why did it change how hormone therapy was prescribed, and what do we know today?
What Was the Women's Health Initiative?
The Women's Health Initiative was a large research program launched in the 1990s to investigate some of the most important health concerns affecting postmenopausal women, including cardiovascular disease, cancer, and osteoporosis.
One component of the research examined whether hormone therapy could help prevent chronic diseases in postmenopausal women.
The hormone therapy trials included two different groups:
Women with a uterus: Received oral conjugated equine estrogens (CEE) combined with medroxyprogesterone acetate (MPA), a synthetic progestin.
Women without a uterus: Received oral estrogen alone.
In July 2002, researchers announced that the estrogen-plus-progestin trial was being stopped early because the overall risks of treatment exceeded the benefits according to the study's predefined safety criteria.
The findings suggested an increased risk of breast cancer, blood clots, stroke, and certain cardiovascular events among women taking the combined therapy.
The headlines were alarming, and the message many women and healthcare providers took away was simple: hormone therapy is dangerous.
Almost overnight, hormone therapy prescriptions declined, and many women discontinued treatment or avoided starting it altogether.
What Did We Miss in 2002?
The WHI was an important study, and its findings identified real risks associated with certain hormone therapy regimens. However, as researchers continued to analyze the data, several important details became clearer.
1. The Age of the Women Studied Matters
The average age of women participating in the WHI hormone trials was approximately 63 years old.
Many participants were more than a decade past menopause when they started treatment.
This is important because starting hormone therapy at age 63 is not necessarily the same as starting treatment at age 48 or 52, when menopausal symptoms commonly develop.
Subsequent analyses suggested that cardiovascular outcomes may differ depending on a woman's age and how long it has been since menopause.
Today, guidelines generally recognize that for healthy women younger than 60 or within 10 years of menopause onset, the benefits of hormone therapy for symptom management often outweigh the risks, provided there are no contraindications.
2. Not All Hormone Therapy Is the Same
One of the biggest misconceptions following the WHI was that the results applied equally to every type of hormone therapy.
But the study evaluated specific oral hormone formulations.
The combined hormone therapy trial used conjugated equine estrogens and medroxyprogesterone acetate.
Today, other options are commonly prescribed, including:
Transdermal estradiol: Estrogen delivered through a patch or gel.
Oral micronized progesterone: A progesterone formulation that differs from the synthetic progestin used in the WHI.
Individualized dosing: Treatment tailored to symptoms, medical history, and personal risk factors.
Research suggests that transdermal estrogen may carry a lower risk of blood clots than oral estrogen, while micronized progesterone may have a different breast and cardiovascular risk profile than some synthetic progestins.
However, it is important to recognize that long-term randomized trial data directly comparing all modern hormone therapy formulations are limited.
We cannot assume that every hormone therapy option has the same risks or that newer formulations are entirely risk-free.
3. The Breast Cancer Findings Were More Nuanced Than the Headlines Suggested
One of the most concerning findings from the WHI was the reported increase in breast cancer risk.
In the combined estrogen-plus-progestin trial, researchers identified approximately eight additional invasive breast cancer cases per 10,000 women per year compared with placebo during the initial reporting period.
While this increased risk was important, the absolute numbers were often missing from public discussions.
Interestingly, the estrogen-only trial in women who had undergone a hysterectomy did not demonstrate the same increase in breast cancer risk. Longer-term follow-up found a reduction in breast cancer incidence in that group.
These findings highlight an important distinction: estrogen-only therapy and combined estrogen-progestogen therapy do not have identical risk profiles.
The type of hormones used, duration of treatment, and individual risk factors all matter.
What Do We Know About Menopausal Hormone Therapy Today?
More than 20 years after the original WHI announcement, our understanding of hormone therapy has become significantly more individualized.
Current evidence supports menopausal hormone therapy as the most effective treatment for vasomotor symptoms, including hot flashes and night sweats.
Hormone therapy can also help prevent bone loss and reduce fracture risk while treatment is being used.
For many healthy women who begin treatment before age 60 or within 10 years of menopause, the overall benefit-risk balance is favourable when hormone therapy is prescribed for appropriate indications.
However, hormone therapy is not recommended solely to prevent cardiovascular disease or dementia, and it is not appropriate for everyone.
A history of certain cancers, unexplained vaginal bleeding, blood clots, stroke, cardiovascular disease, or liver disease may affect whether systemic hormone therapy is appropriate.
The goal is not to prescribe hormones to every woman experiencing menopause. It is to ensure women have accurate information and access to an individualized discussion about their treatment options.
Why Does the WHI Still Matter?
The WHI fundamentally changed how healthcare providers approached menopause.
For years, many women were told to simply tolerate their symptoms or that hormone therapy was too risky to consider.
While the original findings raised legitimate safety concerns, the way those findings were communicated often lacked the context needed for informed decision-making.
Today, we understand that menopause care requires more than a one-size-fits-all approach.
Age, time since menopause, symptom severity, medical history, personal preferences, and the specific hormone formulation all influence treatment decisions.
The most important lesson from the WHI is not that hormone therapy is universally safe or universally dangerous.
It is that the right treatment depends on the right patient, the right formulation, and the right timing.
Considering Hormone Therapy for Perimenopause or Menopause?
If you are experiencing symptoms of perimenopause or menopause, you deserve to understand your treatment options without fear or misinformation.
Menopausal hormone therapy may be an appropriate option for managing symptoms such as hot flashes, night sweats, and sleep disruption related to vasomotor symptoms.
At Momentum Health in Kelowna, Dr. Brittany Jeffries, ND, works with women navigating perimenopause and menopause to assess their symptoms, review their health history, and discuss evidence-based treatment options, including menopausal hormone therapy when appropriate.
If you are wondering whether hormone therapy is right for you, book an appointment to discuss your symptoms and explore your options.